Phapros Focuses on the Development of Innovative Products and Export Business in 2024.

JAKARTA, December 22, 2023 – PT Phapros Tbk, one of the national pharmaceutical companies, continues to maintain its performance by providing innovative products tailored to the needs of the community. The stock code PEHA issuer believes that innovation is a key factor in preserving the company's existence.

David Sidjabat, the Chief Executive Officer of PT Phapros Tbk, stated that to continually drive innovation in new products, they have several strategies. These include a focus on therapy classes in the over-the-counter (OTC) category and the development of biological products such as biomaterials. Various developments are carried out through the A-B-G-C scheme, involving collaboration with strategic partners such as universities and research institutions both domestically and internationally.

"Biomaterial products are a future necessity. Currently, we have a biomaterial product called Bonefill Ortho Cube, a medical device used to fill empty spaces or gaps in bones that facilitates healing or bone regeneration, usually in trauma cases. This product has a high Domestic Content Level (TKDN), exceeding 60%, and is the result of collaboration with Dr. Soetomo Hospital. On the other hand, for the over-the-counter medicine segment, we plan to launch new products with more innovative formulations to complement Phapros' backbone product portfolio, in addition to Antimo, and rejuvenate existing products for performance optimization and extending the product life cycle," he explained.

He added that for the pharmaceutical or biomaterial product roadmap in the next 5 years, Phapros (PEHA) has innovative end-to-end products in antibiotic therapy, antidiabetes, antihypertension, and products to enhance men's stamina, which have been eagerly awaited. These formulations will be developed in innovative dosage forms, including extended release, modified release, or slow release, providing more comfort, lower costs, and better effectiveness. Previously, Phapros launched more than 6 new products throughout 2023, including antituberculosis drugs, multivitamins, and antioxidants.

On the other hand, Phapros has also exported to several countries in the Southeast Asian region such as Cambodia and the Philippines this year. "Cambodia was our first export destination in 2014, and until now they remain loyal customers of Phapros products. This indicates that the products we produce have been tested for quality, not only domestically but also internationally," said David.

David added that the total products exported amounted to more than 40,000 boxes in one shipment. Previously, in April and September 2023, the stock code PEHA issuer also exported various types of drugs to the Philippines.

Not only reaching the Southeast Asian market, but Phapros, along with its subsidiary PT Lucas Djaja Group, has also reached countries in the Middle East to Latin America. David stated that one of the Latin American countries regularly targeted for export is Peru. "Phapros has been regularly exporting its anti-TB drugs to Peru since 2019 because there is no local pharmaceutical company producing TB drugs there, even though, according to the World Health Organization (WHO), the prevalence of TB cases in Peru is the highest in the Americas region," he added.

Meanwhile, Phapros also expressed its readiness to be at the forefront of any potential increase in Covid-19 cases during the long holiday season at the end of 2023. "We also urge the public, especially travelers during this holiday season, to re-implement health protocols, maintain body resistance with a balanced nutritious diet, and consume multivitamin supplements if necessary," he concluded.